A PHASE II STUDY OF VORINOSTAT (MK-0683) IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST-POLYCYTHAEMIA VERA MYELOFIBROSIS (PPV-MF)

被引：0
|
作者：
Andersen, C. [1 ]
Mortensen, N. [1 ]
Vestergaard, H. [2 ]
Bjerrum, O. [3 ]
Klausen, T. [4 ]
Hasselbalch, H. [1 ]
机构：
[1] Roskilde Univ Hosp, Dept Haematol, Roskilde, Denmark
[2] Odense Univ Hosp, Dept Haematol, Odense, Denmark
[3] Copenhagen Univ Hosp, Dept Haematol, Copenhagen, Denmark
[4] Herlev Hosp, Dept Haematol, Herlev, Denmark
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P279
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [41] PHASE 1/2, DOSE-ESCALATION STUDY OF ORAL NS-018 IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (POST-PV MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MF (POST-ET MF)
    Uno, T.
    Verstovsek, S.
    Mesa, R.
    Talpaz, M.
    Ritchie, E.
    Wadleigh, M.
    Odenike, O. M.
    Jamieson, C.
    Stein, B.
    HAEMATOLOGICA, 2015, 100 : 542 - 543
  • [42] A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
    Mascarenhas, John
    Wang, Xiaoli
    Rodriguez, Amelyn
    Xu, Mingjiang
    Gorman, Elaine
    Zhang, Wenyong
    Goldberg, Judith D.
    Najfeld, Vesna
    Hoffman, Ronald
    BLOOD, 2009, 114 (22) : 130 - 131
  • [43] A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    Quintas-Cardama, A.
    Tong, W.
    Kantarjian, H.
    Thomas, D.
    Ravandi, F.
    Kornblau, S.
    Manshouri, T.
    Cortes, J. E.
    Garcia-Manero, G.
    Verstovsek, S.
    LEUKEMIA, 2008, 22 (05) : 965 - 970
  • [44] A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    A Quintás-Cardama
    W Tong
    H Kantarjian
    D Thomas
    F Ravandi
    S Kornblau
    T Manshouri
    J E Cortes
    G Garcia-Manero
    S Verstovsek
    Leukemia, 2008, 22 : 965 - 970
  • [45] Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
    Pardanani, A.
    Tefferi, A.
    Guglielmelli, P.
    Bogani, C.
    Bartalucci, N.
    Rodriguez, J.
    Extremera, S.
    Perez, I.
    Alfaro, V.
    Vannucchi, A. M.
    BLOOD CANCER JOURNAL, 2015, 5 : e286 - e286
  • [46] A Phase 1/2, Open-Label, Dose-Escalation, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen K.
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady L.
    Tomonori, Uno
    Mesa, Ruben
    BLOOD, 2014, 124 (21)
  • [47] Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
    A Pardanani
    A Tefferi
    P Guglielmelli
    C Bogani
    N Bartalucci
    J Rodríguez
    S Extremera
    I Pérez
    V Alfaro
    A M Vannucchi
    Blood Cancer Journal, 2015, 5 : e286 - e286
  • [48] Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis
    Verstovsek, Srdan
    Tefferi, Ayalew
    Korriblau, Steven
    Thomas, Deborah
    Cortes, Jorge
    Ravandi-Kashani, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 1037A - 1037A
  • [49] PHASE II STUDY OF CEP-701, AN ORALLY AVAILABLE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Santos, F. P. S.
    Kantarjian, H.
    Jain, N.
    Thomas, D.
    Garcia-Manero, G.
    Cortes, J.
    Verstovsek, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 439 - 439
  • [50] RUXOLITINIB PLUS PANOBINOSTAT IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A PHASE 1B DOSE-FINDING STUDY
    Vannucchi, A. M.
    Heidel, F. H.
    Ribrag, V.
    Kiladjian, J. J.
    Passamonti, F.
    Hayat, A.
    Conneally, E.
    Kindler, T.
    Martino, B.
    Lipka, D. B.
    Acharyya, S.
    Gopalakrishna, P.
    Loechner, S.
    Mu, S.
    Harrison, C. N.
    HAEMATOLOGICA, 2014, 99 : 129 - 130
12345